Published in J Clin Oncol on June 15, 2002
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol (2009) 2.89
Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci U S A (2007) 2.38
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol (2008) 2.23
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol (2008) 1.86
Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma. JAMA Surg (2016) 1.41
Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol (2009) 1.27
Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol (2009) 1.13
Epidemiology and therapies for metastatic sarcoma. Clin Epidemiol (2013) 1.11
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs (2006) 1.08
Isolated cutaneous metastasis of uterine leiomyosarcoma: case report and review of literature. Diagn Pathol (2012) 1.04
Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. BMC Cancer (2015) 1.04
A rare case of giant leiomyosarcoma in a filarial scrotum: a case report. World J Surg Oncol (2011) 1.03
Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin. Sarcoma (2009) 1.01
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma (2011) 0.98
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2008) 0.96
Systemic therapy for advanced soft tissue sarcomas: highlighting novel therapies and treatment approaches. Cancer (2011) 0.95
Metastatic pleomorphic sarcoma to left atrium. Rare Tumors (2009) 0.95
Malignant fibrous histiocytoma and fibrosarcoma of bone: a re-assessment in the light of currently employed morphological, immunohistochemical and molecular approaches. Virchows Arch (2012) 0.95
A case of intimal sarcoma of the pulmonary artery successfully treated with chemotherapy. Int J Clin Oncol (2011) 0.93
Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline. Curr Oncol (2013) 0.92
Integrative genomic characterization and a genomic staging system for gastrointestinal stromal tumors. Cancer (2010) 0.92
Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line. J Obstet Gynaecol Res (2012) 0.90
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review. BMC Cancer (2013) 0.90
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential. PLoS One (2012) 0.90
The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas. Invest New Drugs (2007) 0.89
Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma. Sarcoma (2015) 0.89
Clinical management of secondary angiosarcoma after breast conservation therapy. Rep Pract Oncol Radiother (2013) 0.87
Primary pericardial sarcoma: a case report and a brief review. Cardiol Res Pract (2011) 0.87
Utility values for advanced soft tissue sarcoma health States from the general public in the United kingdom. Sarcoma (2013) 0.86
Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther (2009) 0.86
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel. Invest New Drugs (2007) 0.85
Trabectedin and its potential in the treatment of soft tissue sarcoma. Ther Clin Risk Manag (2008) 0.84
Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs (2006) 0.84
A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma. Clin Sarcoma Res (2015) 0.83
Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature. BMC Cancer (2011) 0.83
Targeted next-generation sequencing of cancer genes identified frequent TP53 and ATRX mutations in leiomyosarcoma. Am J Transl Res (2015) 0.82
Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report. BMC Gastroenterol (2012) 0.82
Inhibition of uterine sarcoma cell growth through suppression of endogenous tyrosine kinase B signaling. PLoS One (2012) 0.81
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs (2003) 0.81
Systemic therapy in soft tissue sarcomas: past, present and future. Indian J Surg Oncol (2012) 0.81
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors. Invest New Drugs (2007) 0.81
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan. Int J Clin Oncol (2013) 0.81
Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis. Cancer Res Treat (2012) 0.80
New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res (2012) 0.80
A retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomas. Sarcoma (2006) 0.79
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Mar Drugs (2015) 0.79
Recent advances in understanding and managing leiomyosarcomas. F1000Prime Rep (2015) 0.79
Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin. Sarcoma (2015) 0.79
The role of radiation in retroperitoneal sarcomas. Curr Treat Options Oncol (2013) 0.79
Major clinical research advances in gynecologic cancer 2008. J Gynecol Oncol (2008) 0.79
Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd (2015) 0.79
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. World J Gastroenterol (2015) 0.79
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC Cancer (2016) 0.79
[Consensus diagnosis and therapy of soft tissue sarcoma]. Wien Klin Wochenschr (2011) 0.77
Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature. Clin Sarcoma Res (2016) 0.77
Multimodality therapy for metastatic sarcomas confined to the lung. Oncol Lett (2012) 0.77
A Phase II Study of Docetaxel and Epirubicin in Advanced Adult Soft Tissue Sarcomas (STS). Sarcoma (2004) 0.77
Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer (2006) 0.77
Long-term survival in low-grade endometrial stromal sarcoma with childbirth and multidisciplinary treatment: a case report. J Med Case Rep (2015) 0.77
Immunomodulatory effects of docetaxel on human lymphocytes. Invest New Drugs (2003) 0.77
Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer. Wien Klin Wochenschr (2012) 0.76
Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. Mol Clin Oncol (2015) 0.76
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol (2014) 0.76
Role of expert centres in the management of sarcomas. EJC Suppl (2013) 0.75
A Phase Ii Study of Gemcitabine, Vincristine, and Cisplatin (Gvp) As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma. Medicine (Baltimore) (2015) 0.75
VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma. Medicine (Baltimore) (2017) 0.75
The value of perioperative imaging in patients with uterine sarcomas. Gynecol Oncol (2009) 0.75
Potential Therapeutic Targets in Uterine Sarcomas. Sarcoma (2015) 0.75
Case Report: Collision Tumour of Colon Leiomyosarcoma and Adenocarcinoma. J Clin Diagn Res (2016) 0.75
Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report. BMC Cancer (2015) 0.75
Lung metastasis from perineal leiomyosarcoma: a case report and a review of the Japanese literature. Case Rep Med (2013) 0.75
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study. Br J Cancer (2006) 0.75
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). Oncologist (2012) 0.75
Treatment of recurrent metastatic uterine leiomyosarcoma of the spine: a multimodality approach using resection, radiosurgery, and chemotherapy. J Neurosurg Spine (2015) 0.75
Advanced breast angiosarcoma completely responding to gemcitabine-containing chemotherapy. Breast Care (Basel) (2012) 0.75
Advances in the systemic treatment of cutaneous sarcomas. Semin Oncol (2012) 0.75
Pazopanib-mediated long-term disease stabilization after resection of a uterine leiomyosarcoma metastasis to the brain: A case report. Gynecol Oncol Rep (2016) 0.75
Locally-advanced unresected uterine leiomyosarcoma with triple-modality treatment combining radiotherapy, chemotherapy and hyperthermia: A case report. Oncol Lett (2014) 0.75
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol (2015) 0.75
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med (2016) 0.75
Phase II Trial of Angiotensin-(1-7) for the Treatment of Patients with Metastatic Sarcoma. Sarcoma (2016) 0.75
Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services. Clin Sarcoma Res (2016) 0.75
Response of conventional chondrosarcoma to gemcitabine alone: a case report. Clin Sarcoma Res (2015) 0.75
Phase III Soft Tissue Sarcoma Trials: Success or Failure? Curr Treat Options Oncol (2017) 0.75
Uterine leiomyosarcoma manifesting as a tricuspid valve mass. Case Rep Oncol (2013) 0.75
Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. Ecancermedicalscience (2008) 0.75
The role of adjuvant therapy in uterine leiomyosarcoma. Expert Rev Anticancer Ther (2015) 0.75
Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncol Lett (2015) 0.75
Osteosarcoma in Korean children and adolescents. Korean J Pediatr (2015) 0.75
A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer. Springerplus (2014) 0.75
A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D. Gynecol Oncol (2016) 0.75
Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines. Gynecol Oncol Res Pract (2014) 0.75
Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol (2017) 0.75
Prophylactic long-acting granulocyte-colony stimulating factors (G-CSF) in gynecologic malignancies: an oncologic expert statement. Wien Med Wochenschr (2015) 0.75
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol (2017) 0.75
[Uterine sarcoma treatment]. Pathologe (2009) 0.75
Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget (2017) 0.75
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res (2003) 4.55
Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol (2009) 4.11
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res (2002) 3.72
Nomogram to predict cycle-one serious drug-related toxicity in phase I oncology trials. J Clin Oncol (2014) 3.57
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res (2007) 3.53
Patient online self-reporting of toxicity symptoms during chemotherapy. J Clin Oncol (2005) 3.29
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol (2009) 2.97
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg (2001) 2.54
Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol (2009) 2.45
Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res (2007) 2.44
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol (2012) 2.35
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res (2003) 2.32
A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res (2002) 2.21
A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies. Clin Trials (2008) 2.06
Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res (1997) 2.03
Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer (2006) 2.03
Management and outcome of healthy women with a persistently elevated beta-hCG. Gynecol Oncol (2007) 2.01
Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol (2002) 1.99
Laparoscopic-assisted vaginal hysterectomy for endometrial cancer: clinical outcomes and hospital charges. Gynecol Oncol (1999) 1.91
Primary vaginal melanoma: a critical analysis of therapy. Ann Surg Oncol (2004) 1.87
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol (2002) 1.82
Patient-derived xenografts for individualized care in advanced sarcoma. Cancer (2014) 1.82
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. J Clin Oncol (2005) 1.82
Drug development for chronic cancers: time to think differently? J Clin Oncol (2012) 1.72
Proposed revision of the staging classification for esophageal cancer. J Thorac Cardiovasc Surg (1998) 1.69
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res (2010) 1.67
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol (2006) 1.65
The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol (2006) 1.64
Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol (2004) 1.60
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube. Gynecol Oncol (2001) 1.59
The incidence of symptomatic lower-extremity lymphedema following treatment of uterine corpus malignancies: a 12-year experience at Memorial Sloan-Kettering Cancer Center. Gynecol Oncol (2006) 1.51
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res (2012) 1.49
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res (2006) 1.48
Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials. Gynecol Oncol (2007) 1.44
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol (2010) 1.44
En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report. Gynecol Oncol (2006) 1.44
Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol (2007) 1.44
Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol (2005) 1.42
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res (2007) 1.39
Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2011) 1.39
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer (2011) 1.32
Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma. Gynecol Oncol (2005) 1.32
A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res (2005) 1.31
The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg (1996) 1.30
Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res (1995) 1.29
The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol (2007) 1.28
CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol (2006) 1.28
Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol (2002) 1.24
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol (2009) 1.23
Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol (2007) 1.20
Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. Gastroenterology (2012) 1.20
Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol (2000) 1.19
A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin Cancer Res (2012) 1.17
Non-kinase second-messenger signaling: new pathways with new promise. Bioessays (2004) 1.17
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A (2011) 1.16
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol (2013) 1.15
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol (2011) 1.15
High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst (1997) 1.15
Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J Clin Oncol (2004) 1.15
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. Gynecol Oncol (2009) 1.14
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer. Nat Med (2003) 1.12
Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer (2004) 1.12
Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus. J Thorac Cardiovasc Surg (2000) 1.12
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res (2008) 1.12
Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol (2003) 1.12
Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors. Gynecol Oncol (2009) 1.11
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol (2003) 1.10
Retroperitoneal nodal metastasis in primary and recurrent granulosa cell tumors of the ovary. Gynecol Oncol (2006) 1.10
Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol (2004) 1.09
Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res (2009) 1.08
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res (2008) 1.08
The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol (2007) 1.07
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol (2012) 1.06
Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors. Invest New Drugs (2006) 1.05